Avicanna (AVCN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 May, 2026Opening remarks and agenda
Meeting conducted virtually via Lumi platform, enabling live and proxy voting.
Chairman, secretary, and scrutineer appointed; quorum confirmed with 54 shareholders representing 47.12% of shares.
Notice of meeting and voting procedures explained; proof of notice and proxies filed.
Financial performance review
Revenue for 2025 was CAD 25.5 million, with gross profit of CAD 13.5 million and a 53% gross margin, up from 48% in 2024.
Operating expenses decreased by CAD 1.5 million (9% reduction), and adjusted EBITDA improved by 71% year-over-year.
Net loss reduced by 40% to CAD 2.7 million; company operates with zero debt and improved working capital by 23%.
Achieved adjusted EBITDA positivity in Q4 2025; only CAD 1 million raised in 2025 versus CAD 4.8 million in 2024.
Board and executive committee updates
Five directors elected: Aras Azadian, Giancarlo Davila Char, Michael Kott, Ozgur Kilic, and Eileen McCormack.
Ramirez Jimenez International CPAs reappointed as auditors until the next AGM.
Latest events from Avicanna
- Gross margin rose to 53% in 2025, with near break-even EBITDA and global expansion underway.AVCN
Q4 20257 Apr 2026 - Expanding globally with proprietary cannabinoid medicines and platforms, targeting medical markets.AVCN
Life Sciences Virtual Investor Forum23 Mar 2026 - Poised for scale-up in 2026 with new technologies, clinical progress, and global expansion.AVCN
Status Update17 Dec 2025 - Revenue and unit sales grew, international reach expanded, and new IP was secured in Q3 2025.AVCN
Q3 202526 Nov 2025 - Record revenue, margin gains, and global expansion set the stage for 2025 profitability.AVCN
Q4 202424 Nov 2025 - Gross margin rose to 51% in Q2 2025, with positive six-month adjusted EBITDA and expanded product reach.AVCN
Q2 202525 Aug 2025 - Revenue up 75% to $18.8M, gross margin 57%, and EBITDA loss narrowed in Q3 2024.AVCN
Q3 202413 Jun 2025 - Q2 revenue up 85%, gross margin 49%, and adjusted EBITDA loss narrowed by 65%.AVCN
Q2 202413 Jun 2025 - First profitable quarter achieved, driven by margin gains and portfolio expansion.AVCN
Q1 20256 Jun 2025